Please assess the completion status of the following clinical trial:

Trial Title: A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18 years or above~2. Adequate hematologic, hepatic, and renal function~3. Histologically confirmed, new diagnosis of PTCL~4. Eligible for CHOP regimen~5. Measurable disease based on Cheson 2007 criteria~6. Eastern Cooperative Oncology Group (ECOG) performance status \< 2~7. Willing to perform at least two methods of contraception~8. Negative pregnancy test of females with childbearing potential.~Exclusion Criteria:~1. Active concurrent malignancy (except non melanoma skin cancer or carcinoma in situ of the cervix) or life threatening disease. If there is a history of prior malignancies or life threatening diseases, the patient must be disease free for at least 5 years.~2. Congestive heart failure Class III/IV according to the New York Heart Association (NYHA) Functional Classification.~3. Uncontrolled hypertension~4. Central nervous system (CNS) metastases .~5. Active uncontrolled infection, underlying medical condition, or other serious illness that would impair the ability of the patient to receive protocol treatment~6. Major surgery within 30 days prior to enrollment.~7. Use of any investigational drugs, biologics, or devices within 30 days prior or during the study treatment.~8. Previous exposure to pralatrexate.~9. Pregnant or breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part 1: Dose Finding, Cohort 1 (Type: EXPERIMENTAL): Dose finding Phase Intervention: Folotyn (Pralatrexate Injection) CHOP: Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone~The first cohort will begin with three patients with dose A of pralatrexate plus CHOP at full dose.~The second cohort will begin with three patients with dose B of pralatrexate plus CHOP at full dose.~The third cohort will begin with three patients with dose C of pralatrexate plus CHOP at full dose.~The fourth cohort will begin with three patients with dose D of pralatrexate plus CHOP at full dose.~The fifth cohort will begin with three patients with dose E of pralatrexate plus CHOP at full dose.~Part 2: Dose Expansion, Additional ten patients will be enrolled at the MTD or MAD (if the MTD is not reached) plus CHOP at full dose in this part of the study. Blood samples for PK analysis of pralatrexate will be collected at various intervals pre and post pralatrexate injection during cycle 1, Dose 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).